HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WIC reauthorization

This article was originally published in The Tan Sheet

Executive Summary

The Department of Agriculture requests comments on its Women, Infants and Children program as it prepares to work with Congress on the reauthorization of its supplemental nutrition programs in 2009. In a May 20 Federal Register notice, USDA asks for comments, which are due by Oct. 15, to address three themes it proposed to frame reauthorization of WIC and its Child Nutrition Programs: strengthening program management and improving nutrition services, ensuring all eligible persons have access to benefits and advancing technology and innovation. The Natural Products Association has lobbied for WIC coverage to include vitamin D supplementation, a change the USDA did not include in a December 2007 interim rule to revise the program (1"The Tan Sheet" Jan. 14, 2008, p. 10)...

You may also be interested in...



Adding Supplements to Federal Support Programs Needs Industry Push – NPA

A proposal to exclude vitamin D supplementation from a federal nutrition program and continued apathy in Congress toward adding multivitamins and dietary supplements to the food stamp program are signals it is time for the industry to push harder for change, a Natural Products Association executive says

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

UsernamePublicRestriction

Register

RS137371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel